Dizal to Bring Golidocitinib, Birelentinib and GW5282 Data to ASH 2026

Dizal (SSE: 688192) announced it will present the latest clinical results from its hematological disease portfolio at the 68th American Society of Hematology (ASH) Annual Meeting, comprising three oral and five poster presentations. The oral sessions will feature clinical studies evaluating golidocitinib and birelentinib in lymphoma and hematologic immune diseases, while clinical data for GW5282 in relapsed or refractory non-Hodgkin lymphoma (r/r NHL) will be presented for the first time.

Dr. Xiaolin Zhang, CEO of Dizal, said: "Dizal has a globally competitive hematological disease portfolio. Our robust presence at ASH 2026 reflects the exciting advancement of our differentiated portfolio in T-cell and B-cell lymphomas, as well as autoimmune diseases. We believe these programs will bring the next generation of novel therapies to patients globally."

Golidocitinib in PTCL and HLH

Golidocitinib is described by the company as the world's first and only Janus kinase 1 (JAK1) inhibitor approved for the treatment of relapsed or refractory peripheral T-cell lymphoma (r/r PTCL). It has shown promising preliminary efficacy across T-cell lymphoma subtypes and selected hematologic immune diseases, according to the announcement.

• An oral presentation will feature updated data in adults with secondary hemophagocytic lymphohistiocytosis (HLH), extending the previous findings reported at the European Hematology Association (EHA) Congress 2026 (Abstract #PF700). The results demonstrate that golidocitinib, as a single agent, can achieve high and durable response rates with a manageable safety profile, supporting further development of the drug in this disease.
• New data of golidocitinib with CHOP as first-line treatment show promising antitumor activity and a manageable safety profile. These findings support its potential as a frontline treatment option.
• Two real-world retrospective studies of golidocitinib in r/r cutaneous T-cell lymphoma (CTCL) and mycosis fungoides (MF) exhibit robust and durable antitumor activity with a manageable safety profile.
• A preliminary study evaluating golidocitinib combined with PD-1 blockade and asparaginase-containing immunochemotherapy demonstrates encouraging efficacy and a favorable tolerability profile for newly diagnosed and high risk advanced extranodal NK/T-cell lymphoma (ENKTL).

Birelentinib in First-Line CLL/SLL

Birelentinib is described as an innovative dual inhibitor of Lyn and BTK, designed to simultaneously inhibit both BTK-dependent and BTK-independent B-cell receptor (BCR) signaling pathways. Two oral presentations will report data from birelentinib, as a monotherapy or in combination with venetoclax, in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL).

• Birelentinib monotherapy has demonstrated robust antitumor activity, durable responses and favorable tolerability in patients with treatment-naïve and heavily pre-treated CLL/SLL. A global, randomized Phase 3 study is ongoing to compare the efficacy and safety of birelentinib versus investigator's choice of treatment in relapsed or refractory CLL/SLL.
• Birelentinib in combination with venetoclax in treatment-naïve CLL/SLL shows encouraging efficacy and a well-tolerated safety profile, regardless of high-risk genetic features.

GW5282: Preliminary Clinical Evaluation in r/r NHL

GW5282 is a next-generation EZH1/2 dual inhibitor designed to simultaneously inhibit both EZH1 and EZH2 with equal potency, thereby preventing tumor escape due to compensatory activation of EZH1. According to the company, GW5282 showed much improved drug-like properties, with high oral bioavailability, longer half-life, reasonable daily dose, and much improved bone marrow safety.

The emerging clinical data for GW5282 demonstrate an encouraging safety profile and clinical efficacy across multiple r/r non-Hodgkin lymphoma (NHL) subtypes.

Presentation Schedule

Oral Presentations

Poster Presentations

• Prof. Ting Niu: "Updated safety and efficacy of golidocitinib plus CHOP as first-line treatment for peripheral T-cell lymphoma in the phase I/II study (JACKPOT52)." Abstract Number: 1855, Poster Session, 5:30 PM – 7:30 PM CST, Dec 12, 2026.
• Prof. Huiqiang Huang: "Real-world study of golidocitinib monotherapy in relapsed/refractory cutaneous T-cell lymphoma (R/R CTCL): A multicenter retrospective analysis." Abstract Number: 1844, Poster Session, 5:30 PM – 7:30 PM CST, Dec 12, 2026.
• Prof. Liqun Zou: "Real-World Efficacy and Safety of Golidocitinib in Relapsed/Refractory Mycosis Fungoides: Promising Activity in High-Risk Subtypes and Combination Regimens." Abstract Number: 5361, Poster Session, 6:00 PM – 8:00 PM CST, Dec 14, 2026.
• Prof. Liqun Zou: "Frontline Golidocitinib Plus PD-1 Blockade, Gemcitabine, and Pegaspargase for Advanced Extranodal NK/T-Cell Lymphoma: Preliminary Results of a Prospective Phase 2 Study." Abstract Number: 3601, Poster Session, 6:00 PM – 8:00 PM CST, Dec 13, 2026.
• Prof. Huilai Zhang: "A phase I/II study of GW5282, a selective EZH1/2 dual inhibitor, in refractory or relapsed non-Hodgkin lymphomas (BEI-DOU1)." Abstract Number: 5415, Poster Session, 6:00 PM – 8:00 PM CST, Dec 14, 2026.

About Golidocitinib

Golidocitinib is described as the world's first and only JAK1 inhibitor approved for the treatment of r/r PTCL. In June 2024, golidocitinib was approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with r/r PTCL.

At the data cut-off date of August 31, 2023, golidocitinib demonstrated anti-tumor efficacy with an ORR of 44.3%, according to the company. All subtypes benefited, and the ORR of common subtypes exceeded 40%. More than 50% of the patients with tumor remission achieved a complete response with a CRR of 23.9%. Per IRC assessment, the median duration of response (mDoR) reached 20.7 months. As of February 2024, golidocitinib showed a median overall survival (mOS) of 24.3 months.

Golidocitinib was granted Fast Track Designation by the U.S. FDA for the treatment of r/r PTCL in February 2022. In September 2023, the CDE accepted its NDA and granted Priority Review for the treatment of r/r PTCL. The Phase I clinical data of golidocitinib (JACKPOT8 PART A) were published in Annals of Oncology, and global pivotal trial data of golidocitinib for the treatment of r/r PTCL (JACKPOT PART B) were published in The Lancet Oncology.

About Birelentinib

Two resistance mechanisms have been found in patients whose diseases have progressed on a BTK inhibitor treatment: the BTK C481X mutation and BTK-independent BCR signaling pathway activation. Birelentinib is described as a first-in-class, non-covalent, LYN/BTK dual inhibitor with full blood-brain barrier (BBB) penetration, designed to treat both BTK-dependent and BTK-independent B-cell non-Hodgkin lymphoma (B-NHL).

In August 2025, birelentinib was granted Fast Track Designation by the U.S. FDA for the treatment of adult patients with relapsed/refractory CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

About GW5282

GW5282 is a next-generation EZH1/2 (Enhancer of Zeste Homolog 1 and 2) dual inhibitor, preventing EZH1 compensatory activation as a resistance mechanism.

While EZH2 is a clinically validated target for multiple hematological and solid tumors, translational science evidence indicates that inhibiting EZH2 alone often leads to incomplete pathway blockade due to compensatory activation of EZH1, according to the company. Furthermore, approved EZH2-only inhibitors are limited by a short plasma half-life. Consequently, much higher dosing regimens are required to cover the target, leading to high pill burden-related gastrointestinal adverse reactions and dose-limiting bone marrow toxicities.

GW5282 is designed to address these limitations. Available clinical data showed much improved drug-like properties, with high oral bioavailability, longer half-life, reasonable daily dose, and much improved bone marrow safety.

About Dizal

Dizal is a biopharmaceutical company dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of oncology and hematological diseases. Dizal's late-stage portfolio includes two approved drugs and three investigational drugs in late-stage development. ZEGFROVY is approved in both the U.S. and China for the treatment of NSCLC with EGFR exon20ins, with its worldwide development and commercialization rights licensed to AstraZeneca. Golidocitinib is approved in China for the treatment of relapsed and refractory peripheral T cell lymphoma. Birelentinib, a BBB-penetrant LYN/BTK dual inhibitor, is currently in pivotal studies for various hematological diseases. DZD6008, a 4th generation EGFR TKI, and GW5282 are in post Proof-of-Concept studies.